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Abstract
Background
Multiple Sclerosis (MS) is a disease that appreciably impacts on the quality of life of patients
and is associated with high expenditure. MS is a chronic multifactorial disease, character-
ized by inflammation, demyelination and axonal loss. The Brazilian public health system
provides pharmacological treatment as well as hospital and outpatient care for patients with
relapsing-remitting and secondary progressive multiple sclerosis. However, we are not
aware of any previous publications assessing total direct medical costs in patients with a
long follow-up within the Brazilian healthcare system. Consequently, the objective is to ana-
lyze public spending on patients with MS to guide stakeholders in future investment and dis-
investment decisions.
Methods and findings
We retrospectively analyzed public Brazilian spending on patients with MS between 2000
and 2015 using the patient-centered registry of all patients in the public health system (SUS)
obtained through deterministic-probabilistic record linkage of the Outpatient Information
System, Hospital Information System and Mortality Information Systems in Brazil. Descrip-
tive data analysis and a multiple linear regression model was performed to evaluate the
associations between the mean annual cost per patient and the clinical and demographic
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Results
28,401 patients were identified and subsequently 23,082 patients were analyzed. The
majority of the patients were female (73.3%), lived in the southeast region (58.9%), had a
mean age of 36.8 ( 12.2) years and started treatment using one of the interferons beta
(78.9%). The total direct medical cost spending in the sixteen years of the follow-up was US
$ 2,308,393,465.60, and the mean annual expenditure per patient was US $ 13,544.40 (
4,607.05). In the best fit model (p 0.001), approximately 40% of the variability of the mean
annual cost per patient was explained by the region of residence; medication used (intention
to treat); if the patient was a non-exclusive user of medicines, i.e., used SUS for other proce-
dures other than high-cost medicines; year of treatment start; and presence of events
(death; Relapse; change of treatment and/or comorbidity).
Conclusions
In the public health system of Brazil, disease modifying therapies currently represent almost
all of the total direct costs of multiple sclerosis treatment. Around the world, new and emerg-
ing health technologies to treat of MS impose a challenge to health budgets, highlighting the
need for cost-effectiveness studies comparing these technologies to those already avail-
able. Our regression model may help in this process, and calls attention to the need to
access the real world performance of new therapies available in SUS, with the potential for
disinvestment and/ or price reductions if needed.
Introduction
Multiple sclerosis (MS) is a chronic multifactorial disease, characterized by inflammation,
demyelination and axonal loss, mainly in the white matter of the central nervous system. In
most cases, the disease is manifested by neurologic acute symptoms that can be severe or seem
so trivial that the patient may not seek medical care for months or years, usually followed by
period of relief or absence of symptoms; hence, the relapse-remitting characteristic. Spasticity,
optic neuritis, diplopia, paresis or paresthesia of limbs, dysfunctions of coordination and bal-
ance, myelitis, sphincter and cognitive-behavioral dysfunctions, alone or in combination, are
the main symptoms [1]. It was estimated that in Brazil the average prevalence of the disease is
8.69 / 100,000 inhabitants [2]. Most cases occur in young adults between 20 and 50 years of
age, being more frequent in whites and twice as common among women [3].
In general, the diagnosis of MS is based on the occurrence of two or more symptomatic epi-
sodes that should last more than 24 hours each and with different symptoms, separated by at
least one month [1,4]. Radiological and laboratory exams, including magnetic resonance imag-
ing, cerebrospinal fluid analysis and visual evoked potentials, which together contribute to the
clinical evidence, are essential for the diagnosis and monitoring of MS and for treatment [4–
7].
In Brazil, since the enactment of the Federal Constitution of 1988, the right to health is uni-
versal. Thus, the Brazilian public health system, Sistema U´nico de Sau´de—SUS, provides
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diseases; IM, intramuscular; MS, multiple
sclerosis; PPP, purchasing power parity index;
RRMS, relapsing-remitting multiple sclerosis; SC,
subcutaneous; SPMS, secondary progressive
multiple sclerosis; SUS, Sistema U´nico de Sau´de;
ȕINF, interferon beta.
pharmacological treatment; hospital and outpatient care for each Brazilian citizen [8], includ-
ing multiple sclerosis patients diagnosed as relapsing-remitting or secondary progressive mul-
tiple sclerosis (RRMS and SPMS). SPMS includes patients with chronic advanced MS. In
addition to the services offered by the SUS, patients can also choose to contract with private
health plans (supplementary health) [9]. However, only just under a quarter of citizens in Bra-
zil have private insurance 23.6% [10].
The pharmacological options in SUS comprise disease modifying therapies (DMT), usually
high cost drugs including the beta interferons, glatiramer, natalizumab and fingolimod as well
as low cost DMT such as azathioprine. Methylprednisolone is funded for the treatment of
relapses, with medicines also funded for symptomatic relief [1].
In Brazil until 2010, DMT consisted of glatiramer acetate, interferon beta 1a and 1b and aza-
thioprine. In the following years, natalizumab and fingolimod were added as treatment options
from SUS [7,11,12]. However, DMT dispensing in SUS is conditioned on compliance to the
Clinical Guideline of Ministry of Health, which is updated by the National Commission for
Technology Incorporation in SUS, CONITEC [13]. This makes it easier to track patient level
information for these patients. As a result, dispensing information regarding DMT and outpa-
tient procedures, such as treatment for relapses and physiotherapy, are routinely recorded in
the SUS Outpatient Information System. Hospital procedures, such as treatment for relapses
and complications, are recorded in the SUS Hospital Information System. The integration of
these databases, and the Mortality Information System, allows the construction of a robust
patient-centered registry for long term longitudinal follow-up of these patients [14].
MS is a disease that stands out for its appreciable impact on quality of life, as well as the
high cost associated with its treatment [15–17]. Kolasa carried out a systematic review of the
literature that sought to measure the costs of MS treatment. Seventeen studies from 14 coun-
tries were included, of which 16 were retrospective studies based on questionnaires and one
was based on patient records [18]. In most studies, the follow-up period did not exceed three
months. The total direct cost per year per individual ranged from US $ 13,921 to US $ 54,600,
presenting an average of US $ 41,133. Expenses with medicines accounted for 45.7% of direct
costs, while 21.7% were spent on orthopedic appliances and adaptation measures, 15.2% in
hospital care, 13.0% in outpatient care and 4.3% in exams [18].
In a cross-sectional study conducted in Brazil, the total mean annual cost was US $ 19,012.
The cost of DMTs contributed the majority of direct expenditure, especially among those
patients with lower levels of disability, accounting for approximately 90% of the total costs for
mild and moderate MS patients [19]. Hawton and Green demonstrated that treatment expen-
ditures are higher in patients who have outbreaks compared to patients who have not relapsed
in the last six months, and expenditure increased substantially when relapses required hospital
admission [20]. Most published cost effectiveness evaluations of the treatments for MS use
long-term modeling; however, they typically use data from primary studies conducted for a
short period only because of the paucity of studies performed over a long follow-up period]
[21].
In Brazil, despite ongoing constraints and the high cost of DMTs, the long-term spending
on patients with MS within SUS is unknown. In 2015, The QuintilesIMS Institute published a
report that highlights different aspects of the use of medicines in the United States (US), spe-
cially spanning overall spending and patient cost exposure. According to their report, the
spend on DMTs for MS represented the eighth largest drug spending in US in 2014/2015 [22],
endorsing the need to analyse these costs in Brazil for future policy analysis. Consequently, we
believe it is mandatory to analyze actual SUS spending on patients with MS in Brazil, including
long-term follow-up, to guide stakeholders in future investment and disinvestment decisions.
This builds on the recently agreed process formalising disinvestment decisions in Brazil
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including medicines for multiple sclerosis [23,24]. We also hope our results will be useful to
aid future cost-effectiveness analysis of treatments for multiple sclerosis in Brazil and wider.
Methods
Study design and population
We retrospectively analyzed the spending with MS between 2000 and 2015 using the patient-
centered registry obtained through deterministic-probabilistic record linkage of the Outpa-
tient Information System, Hospital Information System and Mortality Information Systems
in SUS. The methodological procedures adopted for the relationship were the same ones
described by Pereira et al. [25]. The monetary values were adjusted according to the purchas-
ing power parity index (PPP) of the World Bank [26].
Patients were included if they were diagnosed with Multiple Sclerosis (G35) according to
the tenth revision of the international classification of diseases (ICD-10) and started DMT
between January 2000 and January 2015. During this period, the following DMT drugs were
available through SUS: three presentations of interferon beta (ČINF), two subcutaneous (SC)
and one intramuscular (IM); glatiramer; natalizumab; fingolimod and azathioprine. We
excluded from the study individuals whose data showed signs of errors during deterministic-
probabilistic record linkage and patients who did not remain in the cohort for at least one year
of observation. All patients were followed until the death or until December 2015 (right cen-
soring). A one year follow-up period was seen as the minimum to start to accurately compute
costs associated with MS.
Costs analysis
The cost analysis took the perspective of the Brazilian Ministry of Health and was limited to
the direct medical costs contained within the registry information systems, which includes the
costs of medicines within the public system. Consequently, we did not include indirect costs in
our analysis. Costs were classified in the following groups: DMT, treatment of relapses, diag-
nostic and monitoring exams, orthopedic appliances and rehabilitation, other outpatient ser-
vices and other hospital services. We included laboratory examinations and visual evoked
potentials as costs associated with monitoring disease progression. The total cost and the rela-
tive frequency were calculated for each category. To describe the evolution of expenditures
according to the year of follow-up (1st year of treatment, 2nd year of treatment, and so on),
the average annual cost per patient was calculated for each of the groups.
The total annual cost per patient was calculated by adding the amount spent on drugs, out-
patient and hospital services for each follow-up year. The mean annual cost per patient, deter-
mined by the central tendency measure of the individual annualized costs, was calculated for
each variable of interest. These were gender, age, region of residence, and the medicines used
for multiple sclerosis at the start of treatment and calendar period in which the patient entered
the registry. We also summarized data on the main comorbidities, and occurrence of relapses,
change of drug during the follow-up period and cause of death. Relapse was defined by the
occurrence of methylprednisolone dispensing and/or pulse steroid therapy and/or hospital
relapse treatment. For the identification of comorbidities, we used the algorithm developed by
Hude Quan et al. [27].
Statistical analysis
Descriptive data analysis was performed calculating the frequency distribution for categorical
variables and measures of central tendency and variability for continuous variables. A multiple
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linear regression model was performed to evaluate the associations between the mean annual
cost per patient and the clinical and demographic variables. We log-transformed the mean
annual expenditure and employed the least squares technique to find the best fit for the data-
set. The suitability of the model was verified from a residue analysis and the level of signifi-
cance adopted was 5%. We performed an additional analysis considering that there are two
types of patients in the SUS: (i) the user of the public health system who accesses various ser-
vices offered which include outpatient and hospital procedures, and (ii) the patient who uses
SUS only to get high-cost drugs and perform the remainder of the treatment through their pri-
vate health plans. The second multiple regression model was constructed from the data of the
first group (i) and aimed to perform a sensitivity analysis. We used the variance inflation factor
(VIF) to rule out the presence of multicollinearity in the model. All analyzes was performed
using R Program 3.4.0 and RStudio 1.0.143.
This research was approved by the Research and Ethics Committee of the Universidade
Federal de Minas Gerais (n˚ 1.072.253).
Results
We identified 28,401 patients within the dispensing registry who had at least one of the DMTs
for the treatment in the period 2000 to 2015. Of these, we excluded 95 (0.33%) patients whose
data indicated an error during the deterministic-probabilistic record linkage and 5,224
patients who did not remain in the cohort for at least one year. At the end, 23,082 patients
were analyzed (Fig 1).
The majority of the patients included in the study were female (73.3%), lived in the south-
east region (58.9%), had a mean age of 36.8 (± 12.2) years and started treatment using one of
the beta interferons (78.9%). The first prescribed DMT was discontinued and changed in 9,835
patients (42.6%). When we analyzed the comorbidities and deaths, we verified that 5,088
(22.0%) patients had a history of one or more comorbidities during the study period, in which
other neurological diseases, paralysis and rheumatoid arthritis were the most frequent. We
found that 1,135 (4.9%) deaths were recorded and the main declared cause was the disease
itself (38.59). The total spending on medicines, outpatient and hospital services in the sixteen
years of the follow-up was US $ 2,308,393,465.60, and the mean annual expenditure per patient
was US $ 13,544.40 (± 4,607.05). The annual cost per patient with high-cost drugs, hospital
and outpatient services, distributed according to the clinical and demographic variables of the
population are reported in Table 1.
The cost of DMTs accounted for 99% of the total cost, and most patients (56.1%) used SUS
only to have access to high-cost drugs. DMT dispensing accounted for 69% of all procedures
captured in the registry. Diagnostic examinations and monitoring were the services most fre-
quently used (47%), although spending on these procedures represented only 14% of the total
cost. Magnetic resonance imaging was the most common examination, representing the
higher relative frequency in this category (45.5%) (Fig 2). Fig 2 combines the average costs for
each service building on Table 1 (which includes information on SDs).
When we analyzed the other categories, we verified that physiotherapy (52.9%) was the ser-
vice with the highest relative frequency in "orthopedic appliances and rehabilitation", as was the
case with the use of antiepileptic drugs (11.5%), clinical consultations (9.2%) and use of periph-
eral muscular relaxants (8.5%) in the category "other outpatient services". In "other hospital ser-
vices", clinical hospital care (50.9%) and surgeries (30.0%) were the most frequent services.
During the follow-up years, there was a decrease in the mean annual cost per patient with
DMTs. In contrast, spending on hospital services and the treatment of relapses showed a
growth trend over the years (Fig 3).
The long-term costs for treating multiple sclerosis in a cohort study
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In the best fit model (p<0.001), approximately 61% (Multiple R-squared: 0.6109, Adjusted
R-squared: 0.6106) of the variability of the mean annual cost per patient was explained by the
region of residence; medication used (intention to treat); if the patient was a non-exclusive
user of medicines, i.e., used SUS for other procedures beyond high-cost drugs dispensed; year
of the start of treatment; and presence of events (death, relapse, change of treatment and/or
comorbidity) (Table 2).
Using SC ČINF-1a and natalizumab at the start of treatment increased by 18% and 11%,
respectively, the mean annual cost per patient compared to patients using IM ČINF-1a. Having
used SC ČINF-1b, glatiramer or azathioprine, reduced the cost by 8%, 12% and 99%, respec-
tively, compared to the use of IM ČINF-1a, with the other variables constant. The increase in
the mean annual cost per patient was inversely proportional to the year of start of treatment,
but directly proportional to the time of treatment.
When analyzing treatment failures, in general the presence of any event, as well relapse,
relapse followed by death, death and when the patient has a record of relapse, switched medi-
cation and death, increased the mean annual expenditure when compared to patients who did
not experience any of these events. In turn, patients who had a switched medication record
showed a reduction of expenditure by 7%. The same occurred for patients who switched their
medication and died, and those who had a relapse and switched medication, who had a reduc-
tion of spending by 5%.
Patients living in the south, northeast, southeast and midwest regions of Brazil had an aver-
age annual cost per patient higher than the patients in the northern region of Brazil. Patients
Fig 1. Patient disposition flow diagram. Patient disposition flow diagram showing patients included and excluded from the study cohort.
https://doi.org/10.1371/journal.pone.0199446.g001
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Table 1. Mean annual cost per patient according to clinical and demographic variables, DMT drug at study entry and sequence of events for the 23,082 MS patients.
Brazil: 2000–2015.
Variables N (%) Mean annual cost per patient (US $, SD)
Cohort 23082 (100.00) 13.544.40 (± 4.607.05)
Gender Female 16919 (73.30) 13,537.81 (± 4,590.97)
Male 6163 (26.70) 13,561.23 (± 4,664.22)
Age 0–17 833 (3.61) 12,295.33 (± 4,001.04)
18–25 3359 (14.55) 13,270.51 (± 4,449.04)
26–35 6988 (30.27) 13,346.65 (± 4,573.04)
36–45 6216 (26.93) 14,273.69 (± 4,836.83)
46–55 4163 (18.04) 13,478.47 (± 4,806.85)
56–65 1280 (5.55) 12,322.51 (± 4,319.04)
> 65 243 (1.05) 12,103.21 (± 4,366.05)
Geographic region Southeast 13605 (58.94) 13,834.53 (± 4,985.88)
South 4458 (19.31) 12,644.44 (± 4,376.67)
Northeast 2644 (11.45) 12,727.25 (± 4,636.75)
Midweast 2025 (8.77) 13,964.30 (± 4,688.50)
North 350 (1.52) 11,233.12 (± 4,363.80)
DMT
(at start of treatment)
Subcutaneos interferon beta 1a (Rebif™) 7881 (34.14) 16,913.10 (± 6,799.14)
Intramuscular interferon beta 1a (Avonex™) 5450 (23.61) 11,522.19 (± 4,489.08)
Subcuaneous interferon beta 1b (Betaferon™ or Extavia™) 4886 (21.17) 12,661.66 (± 4,251.33)
Glatiramer (Copaxone™) 3953 (17.13) 9,659.48 (± 3,772.44)
Azathioprine 672 (2.91) 4,822.24 (± 2,652.35)
Natalizumab (Tysabri™) 144 (0.62) 8,668.26 (± 4,651.24)
Other DMT Combinations 96 (0.42) 10,909.20 (± 5,090.78)
Period of study entry 2000 a 2003 4611 (19.98) 18,239.78 (± 7,959.18)
2004 a 2007 5039 (21.83) 14,943.18 (± 7,411.10)
2008 a 2011 8070 (34.96) 11,528.00 (± 5,574.57)
2012 a 2015 5362 (23.23) 8,324.58 (± 3,268.17)
Events Censorship 11888 (51.50) 12,810.40 (± 4,218.30)
Treatment failure (global) 11194 (48.50) 14,098.78 (± 5,099.70)
Treatment failure (relapses) 2171 (9.41) 12,664.85 (± 5,684.52)
Treatment failure (switched the medication) 9835 (42.60) 14,215.30 (± 5,133.79)
Treatment failure (death) 1135 (4.92) 13,800.46 (± 5,837.92)
Cause of Death
(ICD-10)
Multiple Sclerosis (G35) 438 (38.59) 10,475.94 (± 6,316.14)
Acute myocardial infarction (I219) 37 (3.26) 15,299.95 (± 4,984.23)
Other disorders of the urinary tract (N390) 26 (2.29) 14,993.01 (± 6,573.97)
Other septicemia (A419) 25 (2.20) 12,344.86 (± 5,435.85)
Pneumonia unspecified (J189) 24 (2.11) 19,197.85 (± 6,675.30)
Other Causes 585 (51.54) 12,923.32 (± 4,309.42)
Comorbidity Paralysis 1312 (18.77) 12,166.62 (± 5,564.66)
Rheumatoid arthritis/collagen vascular diseases 912 (13.05) 12,412.63 (± 6,516.65)
Liver disease 543 (7.77) 16,164.83 (± 5,823.15)
Renal failure 461 (6.60) 16,897.48 (± 7,955.72)
Psychoses 321 (4.59) 14,142.52 (± 5,216.06)
Depression 122 (1.75) 12,029.42 (± 4,999.55)
Other neurological disorders 1959 (28.04) 11,680.16 (± 5,532.18)
Others Comorbidities 1357 (19.42) 13,379.96 (± 6,949.39)
 The ICD-10 coding algorithms for these comorbidities are shown in Hude Quan et al study [27].
https://doi.org/10.1371/journal.pone.0199446.t001
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in the midwest region (p<0.001) contributed most to this increase in comparison to others,
since this region showed an increase in spending of 18% compared to the northern region of
Brazil. Patients who used hospital and outpatient services, in addition to high-cost medicines,
had lower annual costs per patient than patients who accessed SUS only to obtain drug treat-
ment (p<0.001).
In the sensitivity analysis, focusing on patients that used SUS for more than just medication
access, the best fit model (p<0.001) showed that approximately 60% (Multiple R-squared:
0.6056, Adjusted R-squared: 0.6053) of the variability of the mean annual cost per patient was
explained by the same predictive variables of the first model (Table 3).
The results in the analysis with the restricted group were very similar to the original model
for almost all variables (DMT, region of residence, year of treatment start, treatment time and
registry of comorbidities), changing only the value of the beta coefficient. However, when ana-
lyzing the events that may indicate some failure of the treatment, we verified that unlike the
first mode the expenditure with patients who presented a relapse is lower by 3% compared to
those who did not present any event. However, it is important to note that this result was not
significant (p = 0.066).
Fig 2. Total average cost and relative frequency of services in the MS cohort.
https://doi.org/10.1371/journal.pone.0199446.g002
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Discussion
The costs of treating patients diagnosed with MS were influenced by clinical and demographic
factors. When we analyze the mean annual cost per patient, the costs varied according to the
region, health policy and type of methodology employed. Several studies have presented simi-
lar costs to those recorded in our cohort (US $ 13,544), such as the results found by Prescott
et al (US $ 12,879), Silva et al (US $ 19,012.32) and Palmer et al when just direct costs are con-
sidered [20,28,29]. However, Curkendall et al suggested higher annual costs between $28,280
and $29,102 depending on the stage of the MS [30]. Patti et al also suggested higher annual
costs at ½18,030/ patient.[31]. Kolbet et al also found that costs are dependent on the availabil-
ity, use and price of services and on disease severity. All of these varied between countries,
leading to very different mean annual costs per patient. In their study, overall mean costs (in
½ PPP) for patients with mild, moderate and severe disease were ½22,800 (range of country
means, 12,600–27,300), 37,100 (22,500–54,700) and 57,500 (27,500–77,600), respectively [32].
Consequently, it is important to put any costs into context.
The majority of the population studied was female (73.3%). This is perhaps not surprising
as multiple sclerosis is twice as common among women than men [3,31]. The reason for this
difference is not fully understood, although it is likely to be associated with socioenvironmen-
tal factors, with underlying genetic differences [1].
Almost eighty percent of the patients started treatment with one of the beta interferons,
which is in accordance with the Brazilian clinical protocol funded within SUS. Until 2017,
Fig 3. Average annual cost per patient and follow-up time, adjusted by PPP index.
https://doi.org/10.1371/journal.pone.0199446.g003
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these drugs and glatiramer were the only ones provided by the Brazilian public health as first
line of treatment of multiple sclerosis. [7,12,14]. This utilisation pattern was also observed by
Moccia et al. that showed SC ČINF-1a was the most prescribed drug for patients with MS in
the 10-year Italian cohort (32.1%), followed by IM ČINF-1a (19.7%) and SC ČINF-1b (16.6%
%). This same study also observed that 53.4% of the patients discontinued the treatment and
switched medication, which was similar to our findings (42.6%) [33].
The most common cause of death in MS patients was "MS" (38.6%). Similar results were
found by Jick et al [34] in which 41% of patients who died had their own disease reported as
death. The second most common cause of death reported in our study patients was acute myo-
cardial infarction (n = 37). When we evaluated the other comorbidities not listed in Table 1
but related to cardiovascular problems, we found that 83 patients reported congestive heart
failure, 25 have cardiac arrhythmias and 25 reported valvular disease.
Studies have also shown that DMTs represent the greater proportion of direct costs within
the treatment of MS, followed by medical consultations and physiotherapy; the latter the most
frequent procedure [35]. DMTs accounted for 99% of healthcare costs in our study, consistent
with the finding by Kolasa et al, which reported that the most important contributions to
direct medical costs were the costs of the medicines [18]. However, appreciably higher than
the 40–46% in the analysis by Curkendall et al depending on the stage of MS and 61–73% in
the study by Patti et al depending onMS type [30,31]. According to the study by Ernstsson O
et al, drugs were the main cost drivers for MS-patients with low disease severity (29% to 82%
Table 2. Multiple linear regression model with multiple sclerosis patients included in the cohort, 2000 to 2015, Brazil.
Predictive variables B Standard Error t value p value
Intercept 8.26E+28 2.036443 32.696 <0.001
South 1.08 0.024993 2.980 0.003
Northeast 1.06 0.025564 2.155 0.031
Southeast 1.16 0.024362 6.146 <0.001
Midwest 1.18 0.026016 6.486 <0.001
Intramscular interfeon beta 1a (Rebif™) 1.18 0.008109 20.376 <0.001
Subcuaneous interferona beta 1b (Betaferon™ or Extavia™) 0.92 0.008959 -9.174 <0.001
Glatiramer (Copaxone™) 0.88 0.009323 -13.622 <0.001
Natalizumab (Tysabri™) 1.11 0.037658 2.678 0.007
Azathioprine 0.06 0.018576 -150.543 <0.001
Other DMT Combinations 0.95 0.046094 -1.111 0.267
Non-exclusive user of medicines 0.89 0.006598 -17.566 <0.001
Year of treatment start 0.97 0.001012 -28.133 <0.001
Treatment time 1.02 0.001159 19.903 <0.001
Registry of comorbidity 0.93 0.007957 -9.187 <0.001
Treatment failure by relapse 1.01 0.017041 0.586 0.558
Treatment failure by switched medication 0.93 0.006856 -10.409 <0.001
Treatment failure by death 1.08 0.020965 3.464 0.001
Treatment failure by relapse and switched medication 0.95 0.014243 -3.889 <0.001
Treatment failure by relapse and death 1.29 0.048735 5.299 <0.001
Treatment failure by switched medication and death 0.95 0.023377 -2.021 0.043
Treatment failure by relapse, switched medication and death 1.04 0.039441 1.003 0.316
 309 (1,3%) outliers were excluded from the model after residue analysis
They were excluded because they showed signs of errors during the parameter data, altering in a significant way the average of the data. However, since outliers do not
represent a population, we preferred to exclude them from analysis.
https://doi.org/10.1371/journal.pone.0199446.t002
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of all costs), while the main cost components for groups with more advanced MS symptoms
were production losses due to MS and informal care (17% to 67%) [36]. As mentioned, we did
not include indirect costs in our study as we took the perspective of the Brazilian healthcare
system. The high proportion of costs for drug treatment in our study can be explained by the
high cost of these medicines relative to other healthcare costs and the fact that a number of
patients, especially those with private insurance, do not use SUS for their follow-up and any
other medical needs—just the cost of the medicines. In Brazil, all citizens are covered by SUS;
however, they can purchase individual or work class health plans for outpatient and hospital
care [9]. Usually high-cost drugs are not included in this modality of health assistance, for
instance, no DMT is currently provided by private health plans; consequently, the high pro-
portion of patients accessing SUS only to have access to these medicines [10]. As a result, there
is typically no record of relapse treatment or other medical assistance in the SUS Information
Systems for these patients influencing our findings.
When analyzing the results of multiple linear regression, the greatest expense associated
that the use of SC INFČ-1a or natalizumab at the start of treatment has a direct relationship
with the high cost of these medicines to the Brazilian Ministry of Health. SC INFČ-1a has the
highest unit value (government acquisition price) in our database, and consequently the
exchange for any other drug in the cohort leads to a decrease in the relative cost. Regarding the
region of residence, higher costs were associated with more developed states where there is a
greater number of qualified professionals and better organizational structure, resulting in
higher availability of doctors, hospitals, outpatient clinics and financial resources. These
regions are the richest and present the best Human Development Index (HDI) in Brazil[37].
In the first regression model with all patients in the cohort, the presence of any event increases
the mean annual cost per patient. The same occurred in the sensitivity analysis with patients
Table 3. Sensitivity analysis of multiple linear regression model with non-exclusive user of medicines. 2000 to 2015.
Predictive variables B Standard Error t value p value
Intercept 3,18E+29 2.048.707 33.158 < 0.001
South 1,09 0.025158 3.255 0.001
Northeast 1,07 0.025732 2.463 0.014
Southeast 1,18 0.024516 6.611 < 0.001
Midwest 1,19 0.026189 6.663 < 0.001
Intramscular interfeon beta 1a (Rebif™) 1,17 0.008160 19.714 < 0.001
Subcuaneous interferona beta 1b (Betaferon™ or Extavia™) 0,91 0.009006 -10.076 < 0.001
Glatiramer (Copaxone™) 0,88 0.009384 -13.880 < 0.001
Natalizumab (Tysabri™) 1,10 0.037908 2.418 0.016
Azathioprine 0,06 0.018689 -150.254 < 0.001
Other DMT Combinations 0,95 0.046405 -1.109 0.268
Year of treatment start 0,97 0.001018 -28.644 < 0.001
Treatment time 1,02 0.001166 19.145 < 0.001
Registry of comorbidity 0,89 0.007546 -15.903 < 0.001
Treatment failure by relapse 0,97 0.016993 -1.836 0.066
Treatment failure by switched medication 0,93 0.006902 -10.424 < 0.001
Treatment failure by death 1,06 0.021090 2.749 0.006
Treatment failure by relapse and switched medication 0,91 0.014159 -6.697 < 0.001
Treatment failure by relapse and death 1,24 0.049005 4.420 < 0.001
Treatment failure by switched medication and death 0,94 0.023526 -2.499 0.012
Treatment failure by relapse. switched medication and death 1,00 0.039628 -0.106 0.915
https://doi.org/10.1371/journal.pone.0199446.t003
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accessing SUS for more than DMT, indicating that, in fact, the more complicated the patient,
the higher the overall cost of treatment.
Recently, there have been debates about medicine incorporation for patients with MS
within SUS [38–40]. As mentioned, first-generation DMTs IFNČ and glatiramer acetate were
incorporated in SUS in 2001 as first line of treatment; natalizumab was incorporated in 2010
as second line and fingolimod was incorporated in 2014 as third line treatment [7,11,12]. How-
ever, there has been a decision to disinvest in IM INF-1a SUS due to its proven inferiority
compared to other pharmaceutical interferon presentations [24, 36]. In 2017, teriflunomide
was incorporated as a first line option for treatment of RRMS after the recommendation of
CONITEC [39]. Following this, fingolimode was also approved for second line of treatment
[39]. Hopefully, spending analyses such as ours will contribute to a more accurate prediction
of future expenditures of patients with MS in Brazil and other countries and helps the Brazilian
healthcare system adapt to these recent changes. We will be monitoring this in the future.
One of the limitations of this study is related to the fact that the information systems used
to compose the registry under study are for administrative purposes. This means that some
clinical information is missing, such as time of diagnosis, Expanded Disability Status Scale
(EDSS) and reasons for DTM switching. This is the same though for most administrative data-
bases. This will be the subject of future research projects in Brazil. It is also important to con-
sider the possibility of incorrect data being incorporated into the system that may culminate in
the sub or overestimation of costs. In addition, as mentioned, some aspects of care are not
included if patients purchased individual private insurance plans or had access to private
insurance via their workplace. In an attempt to minimize possible inconsistencies, after the
data collection, a sample inspection was performed with subsequent cleaning and standardiza-
tion, important stages to guarantee the quality of the collected data. Consequently, we believe
our findings are robust regarding direct medical costs. We are aware that we did not include
indirect costs with authors suggesting that these costs are similar to direct medical costs. How-
ever, our focus was SUS and only direct medical costs.
Conclusions
In the public health system of Brazil, DMTs comprise almost all of the total direct costs of mul-
tiple sclerosis treatment. Around the world, new and emerging health technologies are becom-
ing available to treat of MS. These are typically more expensive than existing treatment,
imposing a challenge to health budgets. As a result, highlighting the need for cost-effectiveness
studies compared to available technologies. We believe our regression model of costs may help
in this process, and calls attention the need to access the real world performance of DTMs
within public healthcare systems to guide future decisions. These can be for either future
investment or disinvestment decisions as well as for future price negotiations within public
systems.
Public sharing of data
The SUS data base is not open for public review with strict regulations and requirements for
access. Researchers can contact the authors for more information if wished regarding the
analysis.
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